MedPath

修正药业集团长春高新制药有限公司

Ownership
-
Established
2002-06-03
Employees
-
Market Cap
-
Website
http://www.china-xiuzheng.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

74

NMPA:74

Drug Approvals

Dapoxetine Hydrochloride Tablets

Product Name
盐酸达泊西汀片
Approval Number
国药准字H20254300
Approval Date
May 27, 2025
NMPA

Moxifloxacin Hydrochloride Eye Drops

Product Name
盐酸莫西沙星滴眼液
Approval Number
国药准字H20244254
Approval Date
Jun 28, 2024
NMPA

Domperidone Tablets

Product Name
多潘立酮片
Approval Number
国药准字H20093061
Approval Date
Oct 10, 2023
NMPA

Tadalafil Tablets

Product Name
他达拉非片
Approval Number
国药准字H20233695
Approval Date
Jun 7, 2023
NMPA

Sildenafil Citrate Tablets

Product Name
枸橼酸西地那非片
Approval Number
国药准字H20233341
Approval Date
Mar 24, 2023
NMPA

Terbinafine Hydrochloride Tablets

Product Name
盐酸特比萘芬片
Approval Number
国药准字H20083816
Approval Date
Nov 7, 2022
NMPA

Tegafur Tablets

Product Name
替加氟片
Approval Number
国药准字H22022854
Approval Date
Jul 27, 2021
NMPA

Hydrotalcite Chewable Tablets

Product Name
铝碳酸镁咀嚼片
Approval Number
国药准字H20065569
Approval Date
Dec 21, 2020
NMPA

Naphazoline Hydrochloride,Chlorphenamine Maleate and Vitamin B12 Eye Drops

Product Name
萘敏维滴眼液
Approval Number
国药准字H20067796
Approval Date
Nov 20, 2020
NMPA

和血胶囊

Approval Number
国药准字Z20063792
Approval Date
Nov 16, 2020
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 8
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.